Extending to the active induction of CD73 expression, within a small study analyzing IFN-beta’s effect on newly diagnosed MS patients, 10 out of 11 patients showed increases in their levels of soluble CD73, which was also associated with a decrease in MS relapse rate (Niemela et al., 2008). The gene discussed is NT5E; the disease is myeloid sarcoma.